The effect of body size on the metabolic clearance of carbamazepine

Biopharmaceutics and Drug Disposition

Volumn 21, Issue 3, 2000, Pages 103-111

  Reith, David M ^a,b   Barry Appleton, D ^a   Hooper, Wayne ^b   Eadie, Mervyn J ^b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Carbamazepine epoxide; Child; Clearance; Metabolism

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; 2 HYDROXYCARBAMAZEPINE; 3 HYDROXYCARBAMAZEPINE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CARBAMAZEPINE ACRIDAN; DRUG METABOLITE; ESTRADIOL; FOLLITROPIN; GLUCURONIDE; LUTEINIZING HORMONE; PROGESTERONE; PROLACTIN; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BODY SIZE; BODY SURFACE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE BLOOD LEVEL; HUMAN; KIDNEY CLEARANCE; LIVER WEIGHT; MALE; MULTIPLE REGRESSION;

ADOLESCENT; ANTICONVULSANTS; BODY HEIGHT; BODY WEIGHT; CARBAMAZEPINE; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE;

EID: 0033660127     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-081X(200004)21:3<103::AID-BDD222>3.0.CO;2-8     Document Type: Article

References (52)

1. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy
2. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy
3. Carbamazepine plasma levels in children and adults: Influence of age dose and associated therapy
4. Carbamazepine and its 10,11-epoxide in children and adults with epilepsy
5. Free and total serum concentrations of carbamazepine and carbamazepine-10,11-epoxide in infancy and childhood
6. Factors influencing plasma concentrations of cbz and cbz-10,11-epoxide in epileptic children and adults
7. Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-10,11-epoxide in serum of children with epilepsy
8. Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children
9. Kinetics of carbamazepine and its 10,11-epoxide metabolite in children
10. Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication
11. Carbamazepine dose-frequency requirement in children
12. Carbamazepine age-dose ratio relationship in children
13. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children
14. Metabolism of carbamazepine
15. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation
16. Metabolism of CBZ by cytochrome P450 isoforms 3A4, 2C8 and 1A2
17. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: Studies with cis-stilbene oxide, carbamazepine 10,11-epoxide and napthalene
18. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma
19. A new N-glucuronide metabolite of carbamazepine
20. Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry
21. A HPLC assay for carbamazepine phase I metabolites and their glucuronides in urine
22. Serum creatinine determination without protein precipitation
23. Urinary excretion of 3-methylhistidine and creatinine by healthy dutch children during day and night. The influence of age and sex
24. Power and sample size calculations: A review and computer program
25. Simplified calculation of body-surface area
26. Calculation of child and adult standard liver volume for liver transplantation
27. Relationship between liver size and body size
28. Appreciation du volume hepatique en fonction de la morphologie de l'individu
29. A simple technique for sonographic estimation of liver volume
30. Measurement of liver volume by emission computed tomography
31. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children
32. Appendix II. Design and optimization of dosage regimens: Pharmacokinetic data
33. Problem of spurious correlation in the evaluation of steady-state carbamazepine levels using metabolite data
34. Liver volume as a determinant of drug clearance in children and adolescents
35. Carbamazepine. Absorption, distribution and excretion
36. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data
37. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation
38. Interactions of valproic acid with carbamazepine and its metabolites' concentrations, concentration ratios, and level/dose ratios in epileptic children
39. Clinically significant drug interactions with carbamazepine: An update
40. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction?
41. Cytochrome P450 in normal pediatric vs adult human liver
42. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 enzymes
43. Serum phenytoin, phenobarbital, carbamazepine, albumin; and plasma estradiol, progesterone concentrations during the menstrual cycle in women with epilepsy
44. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man
45. Effect of human growth hormone on amobarbital metabolism in children
46. Effect of growth hormone on human drug metabolism: Time course and substrate specificity
47. Growth and pubertal maturation in girls with epilepsy
48. Normal pubertal development
49. Diurnal variations in plasma luteinizing hormone, follicle stimulating hormone, and prolactin in boys and girls from birth to puberty